Dr. Frank Haluska is the president and chief executive officer of Anchiano Therapeutics (NASDAQ:ANCN), formerly known as BioCanCell.
Previously, Dr. Haluska oversaw clinical development strategy as senior vice president of clinical research and development and chief medical officer at ARIAD Pharmaceuticals, an oncology company that is now part of Takeda Oncology. At ARIAD, he led the clinical development of Iclusig (ponatinib) through international approvals, as well as the development of Alunbrig (brigatinib) through approval in the U.S.
Dr. Haluska has served as deputy director of the Tufts New England Medical Center Cancer Center, and led the melanoma research programs at the Massachusetts General Hospital Cancer Center and the Dana-Farber Harvard Cancer Center. He also has served as an assistant professor of medicine at Harvard Medical School.
He graduated from Harvard College and the University of Pennsylvania School of Medicine, undertook medical training at MGH and the Dana-Farber Cancer Institute, and completed a fellowship at the Massachusetts Institute of Technology Center for Cancer Research.